RION Launches RION Vet to Advance Platelet-Derived Biologics in Animal Health

Shots: RION has launched RION Vet, a veterinary biotechnology subsidiary, with exclusive global rights to RION’s exosome-based therapeutic platform for animal health RION Vet is developing ePEP-01, a cell-free, shelf-stable platelet-derived biologic, for equine musculoskeletal disorders, which was evaluated in over 50 horses for >4yrs., showing improvement in lameness, with favorable safety RION Vet leverages…

ByRidhi RastogiNovember 12, 2025

NEWS

Dechra Introduces Solovecin to Treat Skin Infections in Dogs and Cats

Shots: Dechra has launched Solovecin (cefovecin sodium) for the treatment of skin infections in dogs & cats across the US Solovecin treats skin infections in dogs (secondary superficial pyoderma, abscesses, & wounds) caused by S. intermedius & S. canis, & in cats (wounds & abscesses) caused by susceptible strains of P. multocida Solovecin, a long-acting…

ByRidhi RastogiNovember 4, 2025

NEWS

Phibro Animal Health Unveils Restoris Piezoelectric Dental Gel for Dogs in the US

Shots: Phibro Animal Health has launched Restoris piezoelectric dental gel for the treatment & support of long-term oral health in dogs with periodontal disease in the US Laboratory & clinical studies showed Restoris reduced periodontal pocket depth & promoted alveolar bone regeneration around treated teeth within 30 days Restoris is applied into periodontal pockets via…

ByRidhi RastogiOctober 31, 2025

NEWS

Zoetis’ Lenivia (Izenivetmab) Receives the CVMP’s Recommendation for Osteoarthritis Pain Relief in Dogs

Shots: The CVMP has recommended Lenivia for the reduction of pain associated with osteoarthritis in dogs, with EC’s decision expected in Q4’25. Also, a commercial launch in the EU is planned for 2026 Lenivia showed increased mobility & decreased pain after a single administration in a 9mos. field study, along with favorable safety in dogs…

ByRidhi RastogiOctober 13, 2025

NEWS

Phibro Animal Health Collaborates with Lighthouse Pharmaceuticals for Novel Canine Periodontal Therapy

Shots: Phibro Animal Health has entered into a licensing agreement with Lighthouse Pharmaceuticals to develop & commercialize a therapeutic asset targeting periodontal health in companion animals As per the agreement, Phibro will obtain exclusive rights to develop, manufacture, and commercialize Lighthouse Pharma’s proprietary compound for canine periodontal care, though financial terms were not disclosed The…

ByRidhi RastogiOctober 10, 2025

NEWS

PetPace Launches Epilepsy Insights Module for Canine Seizure Monitoring

Shots: PetPace has launched an Epilepsy Insights module to deliver low-latency, data-driven insights on epileptic events in dogs; available for beta testing in dogs with a confirmed epilepsy diagnosis The Epilepsy Insights module is powered by the PetPace smart collar & uses AI as well as ML to manage canine epilepsy through continuous monitoring & automated…

ByRidhi RastogiAugust 14, 2025

NEWS

Elanco’s Zenrelia Secures the EC’s Approval to Treat Allergy and Atopic Dermatitis in Dogs

Shots: The EC has approved Zenrelia (ilunocitinib) for the treatment of pruritus linked to allergic dermatitis & clinical symptoms of atopic dermatitis in dogs (≥12mos.) As part of the EU approval process, Elanco conducted an H2H non-inferiority study in 338 dogs across 25 sites in 4 countries, which showed that Zenrelia (QD) is at least…

ByRidhi RastogiJuly 25, 2025

NEWS

ELIAS Animal Health Reports Interim Study Data of ELIAS Cancer Immunotherapy (ECI) in Canine Osteosarcoma

Shots: ELIAS Animal Health has reported interim data from an ongoing study of ELIAS Cancer Immunotherapy (ECI) + CT in dog with osteosarcoma Trial assessed carboplatin (single dose) followed by ECI after 21 days (n=14) vs carboplatin alone (4 doses; n=14), showing 1yr. survival rates of 71% vs 21%; data was presented at ACVIM Forum…

ByRidhi RastogiJune 20, 2025

NEWS

The CVMP Adopts Positive Opinion on Elanco’s Zenrelia for Allergic and Atopic Dermatitis in Dogs

Shots: The CVMP has recommended Zenrelia (ilunocitinib) for the treatment of pruritus linked to allergic dermatitis & clinical symptoms of atopic dermatitis in dogs Opinion was based on clinical data demonstrating quality, safety, efficacy, & a favorable benefit-risk profile incl. a non-inferiority study conducted as a part of the EU approval process Elanco plans to…

ByRidhi RastogiJune 13, 2025

NEWS

Merck Animal Health’s Mometamax Single Receives the US FDA’s Approval to Treat Dogs with Otitis Externa

Shots: The US FDA has approved Mometamax Single (gentamicin, posaconazole, & mometasone furoate otic suspension) to treat otitis externa in dogs; commercially available by the summer of 2025 Mometamax Single has shown favorable efficacy, with 80.5% resolution of clinical signs in dogs vs 19.6% with PBO Mometamax Single is a single-dose in-clinic treatment for otitis…

ByRidhi RastogiMay 5, 2025

RION Launches RION Vet to Advance Platelet-Derived Biologics in Animal Health

Dechra Introduces Solovecin to Treat Skin Infections in Dogs and Cats

Phibro Animal Health Unveils Restoris Piezoelectric Dental Gel for Dogs in the US

Zoetis’ Lenivia (Izenivetmab) Receives the CVMP’s Recommendation for Osteoarthritis Pain Relief in Dogs

Phibro Animal Health Collaborates with Lighthouse Pharmaceuticals for Novel Canine Periodontal Therapy

PetPace Launches Epilepsy Insights Module for Canine Seizure Monitoring

Elanco’s Zenrelia Secures the EC’s Approval to Treat Allergy and Atopic Dermatitis in Dogs

ELIAS Animal Health Reports Interim Study Data of ELIAS Cancer Immunotherapy (ECI) in Canine Osteosarcoma

The CVMP Adopts Positive Opinion on Elanco’s Zenrelia for Allergic and Atopic Dermatitis in Dogs

Merck Animal Health’s Mometamax Single Receives the US FDA’s Approval to Treat Dogs with Otitis Externa

Contact US

OUR INFORMATION

FOLLOW US